Zeitschrift für Rheumatologie

, Volume 69, Issue 9, pp 780–787 | Cite as

Biologika in Schwangerschaft und Stillzeit

Leitthema

Zusammenfassung

Der Einsatz von Biologika-Therapien, insbesondere von TNF-α-Inhibitoren als therapeutisches Konzept bei Patienten mit unzureichendem Ansprechen auf traditionelle Basistherapien, nimmt zu. Frauen mit entzündlich-rheumatischen Erkrankungen benötigen nicht selten eine medikamentöse Therapie in der Schwangerschaft und Stillzeit, hier stellt sich die Frage nach deren Sicherheit. TNF-α-Inhibitoren werden von der FDA in die Kategorie B eingestuft, da keine ausreichenden Daten zur Schwangerschaft beim Menschen vorliegen. Im letzten Jahrzehnt gab es eine wachsende Anzahl von Publikationen mit exponierten Schwangerschaften, insbesondere Fallserien und Registerdaten. Legt man diese zugrunde, haben die bisher vorliegenden Daten keine belastbaren Hinweise auf ein erhöhtes Risiko von Fehlbildungen ergeben. Da nur wenige Fallberichte über eine Exposition während der gesamten Schwangerschaft vorliegen, sollte sicherheitshalber nach der Konzeption abgesetzt werden.

Allerdings kann es in Einzelfällen nach sorgfältiger Abwägung der klinischen Situation begründet sein, die Therapie auch in der Schwangerschaft fortzusetzen. Stillen unter TNF-α-Inhibitoren ist wahrscheinlich sicher. Das fetale Risiko zur Exposition mit anderen Biologika-Therapien wie z. B. Rituximab ist nicht geklärt.

Schlüsselwörter

Rheumatoide Arthritis Therapie TNF-α-Antagonisten Monoklonale Antikörper Rituximab 

Biologics during pregnancy and breast-feeding

Abstract

Over the past years, biological therapies, especially anti-TNF-α antibody therapy has emerged as a treatment approach in patients who have failed to achieve or maintain remission with tradional DMARDs. Women suffering from inflammatory arthritis may need to continue therapy throughout pregnancy and/or in the lactation period, hence the increased concern over the safety of antirheumatic drugs during pregnancy. Anti-TNF agents fall within the US FDA category B concerning fetal risk, indicating that no adequate and well-controlled studies have been conducted in pregnant or lactating women. However, in the last decade, numerous case series and registry data of pregnancies exposed to anti-TNF therapy have accumulated in the literature. According to these data, TNF inhibitor therapies appear to be safe in pregnancy, since no increased risk of malformations has been demonstrated. Ceasing therapy after conception should be considered, but treatment may be continued during pregnancy when indicated.

The use of these agents is likely compatible with breast-feeding. The extent of fetal risk is not clarified for exposure to other biologics, such as Rituximab.

Keywords

Rheumatoid arthritis Drug therapy TNF-α antagonists Antibodies, monoclonal Rituximab 

Literatur

  1. 1.
    Hunt JS, Chen HL, Miller L (1996) Tumor necrosis factors: pivotal components of pregnancy? Biol Reprod 54:554–562CrossRefPubMedGoogle Scholar
  2. 2.
    Toder V, Fein A, Carp H, Torchinsky A (2003) TNF-alpha in pregnancy loss and embryo maldevelopment: a mediator of detrimental stimuli or a protector of the fetoplacental unit? J Assist Reprod Genet 20:73–81CrossRefPubMedGoogle Scholar
  3. 3.
    Berman J, Girardi G, Salmon JE (2005) TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 174:485–490PubMedGoogle Scholar
  4. 4.
    Winger EE, Reed JL (2008) Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol 60:8–16CrossRefPubMedGoogle Scholar
  5. 5.
    Winger EE, Reed JL, Ashoush S et al (2009) Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol 61:113–120CrossRefPubMedGoogle Scholar
  6. 6.
    Treacy G (2000) Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody. Hum Exp Toxicol 19:226–228CrossRefPubMedGoogle Scholar
  7. 7.
    Briggs GG (2005) Drugs in pregnancy and lactation. 7.Aufl. Williams & Wilkins, BaltimoreGoogle Scholar
  8. 8.
    Martin PL, Cornacoff JB, Treacy G et al (2008) Effects of administration of a monoclonal antibody against mouse tumor necrosis factor alpha during pregnancy and lactation on the pre- and postnatal development of the mouse immune system. Int J Toxicol 27:341–347CrossRefPubMedGoogle Scholar
  9. 9.
    Vasiliauskas EA, Church JA, Silverman N et al (2006) Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 4:1255–1258CrossRefPubMedGoogle Scholar
  10. 10.
    Mahadevan U, Terdiman JP, Church J et al (2007) Infliximab levels in infants born to women with inflammatory bowel disease. Dig Dis Week, abstract 959Google Scholar
  11. 11.
    Murashima A, Watanabe N, Ozawa N et al (2009) Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis 68:1793–1794CrossRefPubMedGoogle Scholar
  12. 12.
    Porter C, Kopotsha T, Smith B et al (2010) No significant transfer of certolizumab pegol compared with IgG in the perfused human placenta in vitro. Ann Rheum Dis 69 (Suppl3):210CrossRefGoogle Scholar
  13. 13.
    Nesbitt ABD, Stephens S, Foulkes R (2006) Placental transfer and accumulation in milk of the anti TNF-antibody TN3 in rats: immunoglobulin G1 versus PEGylated FAB. Am J Gastroenterol, abstract 119Google Scholar
  14. 14.
    Oussalah A, Bigard MA, Peyrin-Biroulet L (2009) Certolizumab in pregnancy. Gut 58:608CrossRefPubMedGoogle Scholar
  15. 15.
    Cush JJ (2005) Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis 64:iv18–23CrossRefPubMedGoogle Scholar
  16. 16.
    Ostensen M, Lockshin M, Doria A et al (2008) Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 47:iii28Google Scholar
  17. 17.
    Vinet E, Pineau C, Gordon C et al (2009) Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum 61:587–592CrossRefPubMedGoogle Scholar
  18. 18.
    Ali YM, Kuriya B, Orozco C et al (2010) Can tumor necrosis factor inhibitors be safely used in pregnancy? J Rheumatol 37:9–17CrossRefPubMedGoogle Scholar
  19. 19.
    Katz JA, Antoni C, Keenan GF et al (2004) Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol 99:2385–2392CrossRefPubMedGoogle Scholar
  20. 20.
    Snoeckx Y, Keenan G, Sanders M, Gardiner M (2009) Update on pregnancy outcomes in women taking Infliximab: the Infliximab safety database. Ann Rheum Dis 68 (Suppl 3):122Google Scholar
  21. 21.
    Hyrich K, Watson K, Dixon W et al (2006) Pregnancy experience in women with rheumatic diseases exposed to biologic agents: results from the BSR biologic register. Arthritis Rheum 54:2701–2702CrossRefPubMedGoogle Scholar
  22. 22.
    King Y, Watson KD, Symmons DPM et al (2008) Pregnancy outcome in women exposed to Anti-TNF Agents: An update from the British Society for Rheumatoogy Biologics Register. Arthritis Rheum (Suppl 58):S542 (abstract)Google Scholar
  23. 23.
    Garcia-Gonzalez A, Joven B, Ruiz T et al (2006) Pregnancy in women receiving anti TNF-alpha therapy: experience in Spain. Ann Rheum Dis 65:317 (abstract)Google Scholar
  24. 24.
    Strangfeld A, Listing J, Rau R et al (2007) Pregnancy outcome after exposure to biologics: Results from the German Biologics Register RABBIT. ACR 2007 No. 730 (abstract)Google Scholar
  25. 25.
    Johnson DL, Jones KL, Jimenez J et al (2009) Pregnancy outcomes in women exposed to adalimumab: An update on the autoimmune diseases in pregnancy uroject. http://www.otispregnancy.org/hm/download.php?id=12&client_idGoogle Scholar
  26. 26.
    Johnson DL, Jones KL, Chambers CD (2008) Pregnancy outcomes in women exposed to etanercept. The OTIS autoimmune disease in pregnancy project. http://www.otispregnancy.org/hm/download.php?id=12&client_id)Google Scholar
  27. 27.
    Mahadevan U, Kane S, Sandborn WJ et al (2005) Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn’s disease. Aliment Pharmacol Ther 21:733–738CrossRefPubMedGoogle Scholar
  28. 28.
    Tursi A (2006) Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn’s disease. Dig Liver Dis 8:439–440CrossRefGoogle Scholar
  29. 29.
    Schnitzler F, Fidder HH, Ferrante M et al (2007) Intentional treatment with infliximab during pregnancy in women with inflammatory bowel disease. Dig Dis Week, abstract 958Google Scholar
  30. 30.
    Rosner I, Haddad A, Boulman N et al (2007) Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 46:1508Google Scholar
  31. 31.
    Vesga L, Terdiman JP, Mahadevan U (2005) Adalimumab use in pregnancy. Gut 54:890CrossRefPubMedGoogle Scholar
  32. 32.
    Coburn LA, Wise PE, Schwartz DA (2006) The successful use of adalimumab to treat active Crohn’s disease of an ileoanal pouch during pregnancy. Dig Dis Sci 51:2045–2047CrossRefPubMedGoogle Scholar
  33. 33.
    Mishkin DS, Van Deinse W, Becker JM, Farraye FA (2006) Successful use of adalimumab (Humira) for Crohn’s disease in pregnancy. Inflamm Bowel Dis 12:827–828CrossRefPubMedGoogle Scholar
  34. 34.
    Berthelot JM, De Bandt M, Goupille P et al (2009) Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76:28–34CrossRefPubMedGoogle Scholar
  35. 35.
    Rump JA, Schönborn H (2010) Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment. Z Rheumatol [Epub ahead of print Jun 9]Google Scholar
  36. 36.
    Carter JD, Valeriano J, Vasey FB (2006) Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. J Rheumatol 33:1014–1017PubMedGoogle Scholar
  37. 37.
    Carter JD, Ladhani A, Ricca LR et al (2009) A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 36:635–641CrossRefPubMedGoogle Scholar
  38. 38.
    Amato RJ de, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082–4085CrossRefPubMedGoogle Scholar
  39. 39.
    Østensen M, Förger F, Nelson JL et al (2005) Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann Rheum Dis 64:839–844CrossRefPubMedGoogle Scholar
  40. 40.
    Förger F, Matthias T, Oppermann M et al (2004) Infliximab in breast milk. Lupus 13:753Google Scholar
  41. 41.
    Kane S, Ford J, Cohen R, Wagner C (2009) Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn’s disease before and after delivery. J Clin Gastroenterol 43:613–616CrossRefPubMedGoogle Scholar
  42. 42.
    Ostensen M, Eigenmann GO (2004) Etanercept in breast milk. J Rheumatol 31:1017–1018PubMedGoogle Scholar
  43. 43.
    Berthelsen B, Nielsen HF, Nielsen CT, Hellmuth E (2010) Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology (Oxford) [Epub ahead of print]Google Scholar
  44. 44.
    Ben-Horin S, Yavzori M, Katz L et al (2010) Adalimumab Level in Breast Milk of a Nursing Mother. Clin Gastroenterol Hepatol 8:475–476CrossRefPubMedGoogle Scholar
  45. 45.
    Paschou S, Voulgari PV, Vrabie IG et al (2009) Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab. J Rheumatol 36:351–354PubMedGoogle Scholar
  46. 46.
    Barcelo M, Sellas A, Rodríguez-Diez B et al (2009) Paternity in patients treated with Anti-TNF therapy. ACR 2009 [SAT0279]Google Scholar
  47. 47.
    Suominen JS, Wang Y, Kaipia A, Toppari J (2004) Tumor necrosis factor-alpha (TNF-alpha) promotes cell survival during spermatogenesis, and this effect can be blocked by infliximab, a TNF-alpha antagonist. Eur J Endocrinol 151:629–640CrossRefPubMedGoogle Scholar
  48. 48.
    Said TM, Agarwal A, Falcone T et al (2005) Infliximab may reverse the toxic effects induced by tumor necrosis factor alpha in human spermatozoa: an in vitro model. Fertil Steril 83:1665–1673CrossRefPubMedGoogle Scholar
  49. 49.
    La Montagna GL, Malesci D, Buono R, Valentini G (2005) Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents. Ann Rheum Dis 64:1667CrossRefGoogle Scholar
  50. 50.
    Villiger PM, Caliezi G, Cottin V et al (2010) Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 69:1842–1844CrossRefPubMedGoogle Scholar
  51. 51.
    Murtha AP, Nieves A, Hauser ER et al (2006) Association of maternal IL-1 receptor antagonist intron 2 gene polymorphism and preterm birth. Am J Obstet Gynecol 195:1249–1253CrossRefPubMedGoogle Scholar
  52. 52.
    Sadowsky DW, Adams KM, Gravett MG et al (2006) Preterm labor is induced by intraamniotic infusions or interleukin-1beta and tumor necrosis factor-alpha but not by interleukin-6 or interleukin-8 in a nonhumate primate model. Am J Obstet Gynecol 195:1578–1589CrossRefPubMedGoogle Scholar
  53. 53.
    Berger CT, Recher M, Steiner U, Hauser TM (2009) A patients wish: anakinra in pregnancy. Ann Rheum Dis 68:1794–1795CrossRefPubMedGoogle Scholar
  54. 54.
    Bazzani C, Ramoni V, Scrivo R et al (2010) Pregnancy outcomes in women exposed to biologic treatment and affected by chronic arthritis. Ann Rheum Dis 69 (Suppl 3):678Google Scholar
  55. 55.
    (o A) (2007) Fachinformation Orencia Bristol-Myers SquibbGoogle Scholar
  56. 56.
    Østensen M, Lockshin M, Doria A et al (2008) Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 47(Suppl 3):iii28–31Google Scholar
  57. 57.
    Ishikawa H, Kanamono T, Kojima T et al (2010) Treatment of young female patients with rheumatoid arthritis using biological agents- results from 6 years of clinical practice in Japanese TBC registry for the patients with rheumatoid arthritis using biologics. Ann Rheum Dis 69 (Suppl):679CrossRefGoogle Scholar
  58. 58.
    Kimby E, Sverrisdottir A, Elinder G (2004) Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 72:292–295CrossRefPubMedGoogle Scholar
  59. 59.
    Decker M, Rothermundt C, Holländer G et al (2006) Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol 7:693–694CrossRefPubMedGoogle Scholar
  60. 60.
    Friedrichs B, Tiemann M, Salwender H et al (2006) The effects of rituximab treatment during pregnancy on a neonate, Haematologica 91:1426–1427Google Scholar
  61. 61.
    Scully M, Starke R, Lee R et al (2006) Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul Fibrinolysis 17:459–463CrossRefPubMedGoogle Scholar
  62. 62.
    Ojeda-Uribe M, Gilliot C, Jung G et al (2006) Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol 26:252–255CrossRefPubMedGoogle Scholar
  63. 63.
    Klink DT, Elburg RM van, Schreurs MW, Well GT van (2008) Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 27:1363Google Scholar
  64. 64.
    Diaz MC, Gutierrez JJM, Buitrago VV (2008) Rituximab and pregnancy: Case report. EULAR 0448Google Scholar
  65. 65.
    Pellkofer HL, Suessmair C, Schulze A et al (2009) Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler 15:1006–1008CrossRefPubMedGoogle Scholar
  66. 66.
    Rey J, Coso D, Roger V et al (2009) Rituximab combined with chemotherapy for lymphoma during pregnancy. Leuk Res 33:e8–e9CrossRefPubMedGoogle Scholar
  67. 67.
    Ponte P, Lopes MJ (2010) Apparent safe use of single dose rituximab for recalcitrant atopic dermatitis in the first trimester of a twin pregnancy. J Am Acad Dermatol 63:355–356CrossRefPubMedGoogle Scholar
  68. 68.
    Herold M, Schnohr S, Bittrich H (2001) Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 19:3439PubMedGoogle Scholar
  69. 69.
    Magloire LK, Pettker CM, Buhimschi CS, Funai EF (2006) Burkitt’s lymphoma of the ovary in pregnancy. Obstet Gynecol 108:743–745PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Klinik für Endokrinolologie, Diabetologie und Rheumatologie, Rheumazentrum Rhein-RuhrDüsseldorfDeutschland

Personalised recommendations